When AA amyloidosis develops in a patient with familial Mediterranean fever (FMF) or a comparable autoinflammatory syndrome, the persistent inflammatory burden of the underlying condition is the principal driver of amyloid A protein deposition. Controlling that inflammation is the central therapeutic objective.
AA amyloidosis arising in the context of familial Mediterranean fever or another autoinflammatory syndrome. Chronic, recurrent systemic inflammation characteristic of these conditions creates the sustained exposure to serum amyloid A protein that leads to tissue deposition over time.
Management is directed at suppressing the systemic inflammation underlying amyloid deposition. Colchicine is the therapeutic cornerstone in this setting — the specific regimen and clinical decision pathway are detailed in the full structured protocol.
Control of systemic inflammation with serum SAA levels no longer significantly elevated, and remission of the associated AA amyloidosis.
DOI: 10.2147/CLEP.S39981
High-dose colchicine (1.5–2 mg/day) is effective in controlling systemic inflammation in autoinflammatory syndromes, such as FMF, and has been able to induce remission of associated AA amyloidosis.
View source ↗